Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Jounce management will participate in a fireside ch...
Cancer therapeutics have come a long way in the last 10 years, with the rise of cancer immunotherapy and gene therapy providing ever-improving outcomes for patients. Investors keen on profiting from these ongoing and future advances in biomedical science will need to round out their portfolio wi...
Aimed at streamlining its post-Celgene-merger pipeline, Bristol Myers Squibb ( BMY +1.0% ) has terminated the license agreement and returned global rights to JTX-8064 to Jounce Therapeutics ( JNCE +3.0% ). More news on: Bristol-Myers Squibb Company, Jounce Therapeutics, Inc., Healthcar...
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it has regained the worldwide rights to JTX-8064 fr...
CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will now host the Company’s 2020 Annual M...
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced two upcoming virtual poster presentations introducing the...
Jounce Therapeutics, Inc. (JNCE) Q1 2020 Earnings Conference Call May 06, 2020, 08:00 AM ET Company Participants Komal Joshi - IR Rich Murray - CEO & President Beth Trehu - Chief Medical Officer Kim Drapkin - CFO Conference Call Participants Daniel McMahon - Raymond J...
Image source: The Motley Fool. Jounce Therapeutics, Inc. (NASDAQ: JNCE) Q1 2020 Earnings Call May 6, 2020 , 8:00 a.m. ET Operator Continue reading
Jounce Therapeutics (NASDAQ: JNCE ): Q1 GAAP EPS of -$0.78 misses by $0.21 . More news on: Jounce Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Jounce Therapeutics Inc. Company Name:
JNCE Stock Symbol:
NASDAQ Market:
Jounce Therapeutics Inc. Website:
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Co...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or t...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE)...